
Dec 23 (Reuters) - Reviva Pharmaceuticals Holdings Inc RVPH.O:
REVIVA PHARMACEUTICALS: RECOVER-2 TRIAL PROJECTED TO COST ABOUT $60 MILLION
REVIVA PHARMACEUTICALS: MAY INITIATE PHASE 3 TRIAL OF BRILAROXAZINE FOR NEGATIVE SYMPTOMS OR BIPOLAR DISORDER IN Q2 2026
REVIVA PHARMACEUTICALS: NEGATIVE SYMPTOMS/BIPOLAR TRIAL IS PROJECTED TO COST ABOUT $30 MILLION
Source text: [ID:n0001437749-25-038602]